Table 3.
Comparison of patients who died or survived*.
| Died (n = 13) | Survived (n = 33) | P | |
|---|---|---|---|
| n (%) | n (%) | ||
| Age, years | 61±10.6 | 65.9 ± 9.8 | 0.77 |
| BMI, kg/m2 | 30.8 ± 4.8 | 28.2 ± 4.0 | 0.23 |
| FVC (L) | 2.0 ± 0.8 | 2.4 ± 0.7 | 0.30 |
| FVC,% | 63.2 ± 13.3 | 75.5 ± 78.7 | 0.22 |
| DLCO,% | 35.6 ± 12.6 | 47.8 ± 14.1 | 0.14 |
| Pirfenidon | 11 (84.6) | 20 (60.6) | 0.17 |
| DLCO/VA | 51.21±19.0 | 68.4 ± 21.2 | 0.03 |
| 6 MWT (m) | 277.5 ± 13.7 | 352.0 ± 73.8 | 0.33 |
| SPO2 (min) | 87.2 ± 4.7 | 89.3 ± 4.8 | 0.26 |
| Fever | 4 (30.8) | 17 (51.5) | 1.00 |
| Dyspnea | 7 (53.9) | 20 (60.6) | 0.07 |
| Cough | 4 (30.8) | 13 (39.4) | 0.43 |
| Consolidation | 5 (38.5) | 6 (18.2) | 0.005 |
| Systemic corticosteroid use | 7 (53.9) | 25 (75.8) | 1.00 |
| Plasma treatment | 6 (38.5) | 6 (18.2) | <0.001 |
| Favipiravir | 5 (38.5) | 18 (54.6) | 1.00 |
| Antibiotic use | 5 (38.5) | 9 (27.3) | 0.10 |
| Comorbidity | 11 (84.6) | 31 (93.9) | 0.56 |
| Male sex | 9 (69.2) | 19 (57.6) | 0.69 |
| LTOT | 7 (53.9) | 7 (21.2) | 0.04 |
BMI: Body mass index; MWT: minute walk test; LTOT: long term oxygen treatment *Data are mean (SD) based on N unless stated otherwise. Percentages are based on N unless stated otherwise.